Proposed Agenda & Faculty, July 7 - 8 2023
07:00am
Registration
07:50am
Opening Introduction to the meeting – Ryan Fitzpatrick, CEO, MD Education
Session I
Moderator – Farhad Ravandi and Eytan Stein
08:00am
The genetic landscape and molecular diagnostics in AML
Joe Khoury, University of Nebraska Medical Center
08:20am
Optimizing frontline therapy for FLT3 mutated AML patients eligible for Intensive Chemotherapy
Harry Erba, Duke Blood Cancer Center, Durham
08:40am
Genomic strategies to guide the choice of intensive treatment strategies in non-FLT3m AML
Amir Fathi, Massachusetts General Hospital, Boston
09:00am
Diagnostic and Molecular Work-up of Newly Diagnosed AML- The Pathologists’ Perspective
Sanam Loghavi, MD Anderson Cancer Center Houston, Texas
9:20am
Panel Discussion
9:40am
Coffee Break
Session II
Moderator – Marina Konopleva and Amir Fathi
10:00am
Updates on the management and mechanisns of resistance in R/R FT3 mutated AML
Alexander E. Perl, Hospital of University of Pennsylvania, Philadelphia PA
10:20am
How do I assess for MRD in clinical practice and how do I use MRD to guide post remission therapy
Farhad Ravandi, MD Anderson Cancer Center Houston, Texas
10:40am
How do I use IDH inhibitors in the frontline and R/R Setting: Single agent versus combinations
Courtney DiNardo, MD Anderson Cancer Center Houston, Texas
11:00am
Current status and future directions with menin inhibitors in AML
Eytan Stein, Memorial Sloan Kettering Cancer Center, New York
11:20pm
Panel Discussion
11:40pm
Lunch Break
Session III
Moderator – Tapan Kadia and Hetty Carraway
Debate 1: Triplets in the treatment of newly diagnosed AML
12:30pm
The case for upfront triplets
Naval Daver, MD Anderson Cancer Center, Houston, Texas
12:40pm
The case for sequential triplets
Jessica Altman, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois
12:50pm
Panel Discussion
13:00pm
Developing immune and cellular therapies in AML
Yasmin Abaza, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois
13:20pm
How do I Manage AML Patients Receiving HMA/venetoclax based therapies; A focus on practical approaches
Brian Jonas, UC Davis Health, Sacramento, CA
13:40pm
Panel Discussion
14:00pm
Coffee Break
Session IV
Moderator – Alexander Perl and Courtney DiNardo
14:20pm
Mechanisms of resistance and novel combinations with venetoclax based therapies in AML
Marina Konopleva, MD Anderson Cancer Center Houston, Texas
14:40pm
Optimizing maintenance therapy in AML post-consolidation and post-transplant
Tapan Kadia, MD Anderson Cancer Center, Houston, Texas
15:00pm
Immune based approaches in AML/MDS
Hetty Carraway, Cleveland Clinic, Ohio
15:20pm
Optimizing SCT approaches including conditioning and maintenance in AML
Andrew Artz, City of Hope, Chicago, Illinois
15:40pm
Panel Discussion
16:00pm
Astellas Sponsored Expert Discussion
16:50pm
Adjourn
08:00am
Registration
Session V
Moderator – Anjali Advani and Ryan Cassaday
09:00am
Incorperating targeted therapies: Menin, FLT3, IDH and others in pediatric populations
Branko Cuglievan, MD Anderson Cancer Center, Houston, Texas
09:20am
The genetic landscape and molecular diagnostics in ALL
Charles Mullighan, St. Jude Children’s Research Hospital, Memphis, Tennessee
9:40am
Walking away from chemotherapy
Elias Jabbour, MD Anderson Cancer Center, Houston, Texas
10:00am
When to transplant in ALL
Mark Litzow, Mayo Clinic Comprehensive Cancer Center
10:20am
Panel Discussion
10:50am
Coffee Break
Session VI
Moderator – Wendy Stock and Nitin Jain
Debate 1: Integration of immunotherapy into frontline therapy
11:10am
Inotuzumab
Ryan Cassaday, Fred Hutchinson Cancer Center, Seattle, Washington
11:20am
Blinatumomab
Anjali Advani, Cleveland Clinic, Ohio
11:30am
Discussion
11:40am
How to approach Ph-like ALL
Marina Konopleva, MD Anderson Cancer Center, Houston, Texas
12:00pm
How to tailor therapy according to MRD: when to escalate and when to de-escalate
Aaron Logan, University of California, San Francisco
12:20pm
Panel Discussion
12:40pm
Lunch Break
Session VII
Moderator – Aaron Logan and Shira Dinner
Debate 2: Relapsed-Refractory disease
13:30pm
Immunotherapy in ALL
Elias Jabbour, MD Anderson Cancer Center, Houston, Texas
13:40pm
CAR T-cells in ALL
Bijal Shah, Moffitt Cancer Center, Tampa, Florida
13:50pm
Discussion
14:00pm
BCL2 inhibitors in ALL
Marlise Luskin, Dana-Farber Cancer Institute, Boston, Massachusetts
14:20pm
How to optimize pediatric regimens and the use of asparaginase
Wendy Stock, The University of Chicago
14:40pm
Panel Discussion
15:00pm
Coffee Break
Session VIII
Moderator – Bijal Shah and Marina Konopleva
15:20pm
Novel agents and pathways in T-ALL and ETP-ALL
Nitin Jain, MD Anderson Cancer Center, Houston, Texas
15:40pm
Novel CAR T approaches
Regina Myers, Childrens Hospital of Philadelphia
16:00pm
Older adults with ALL
Shira N Dinner, Northwestern Medicine, Feinberg School of Medicine, Chicago, IL
16:20pm
Future of ALL therapies
Hagop Kantarjian, MD Anderson Cancer Center, Houston, Texas
